Profile data is unavailable for this security.
About the company
Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company, which is engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. The Company’s initial focus is on the development of Pritumumab as an intravenous treatment of patients with various types of brain cancer, prominently gliomas and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.
- Revenue in USD (TTM)0.00
- Net income in USD-1.92m
- Incorporated2009
- Employees--
- LocationNascent Biotech Inc631 Us Hwy 1, Suite 407NORTH PALM BEACH 33408United StatesUSA
- Phone+1 (612) 961-5656
- Websitehttps://www.nascentbiotech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Imunon Inc | 0.00 | -19.45m | 10.05m | 33.00 | -- | 1.23 | -- | -- | -1.89 | -1.89 | 0.00 | 0.5649 | 0.00 | -- | -- | 0.00 | -99.63 | -50.18 | -137.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
| Vaccinex Inc | 388.00k | -18.58m | 10.06m | 37.00 | -- | -- | -- | 25.93 | -12.15 | -12.15 | 0.2512 | -0.5081 | 0.1047 | -- | 0.4046 | 10,486.49 | -501.27 | -262.29 | -- | -- | -- | -- | -4,787.89 | -4,257.17 | -- | -49.48 | -- | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Dominari Holdings Inc | 12.59m | -22.69m | 10.23m | 26.00 | -- | 0.2673 | -- | 0.8126 | -3.85 | -3.85 | 2.11 | 6.10 | 0.2361 | -- | 3.80 | 484,192.30 | -42.55 | -26.82 | -44.27 | -27.45 | -- | -- | -180.22 | -3,353.52 | -- | -4.83 | 0.00 | -- | -- | 135.75 | 12.72 | -- | 63.99 | -- |
| Oncotelic Therapeutics Inc | 0.00 | -4.66m | 10.31m | 22.00 | -- | 1.17 | -- | -- | -0.0115 | -0.0115 | 0.00 | 0.0217 | 0.00 | -- | -- | 0.00 | -17.29 | -25.03 | -39.98 | -48.76 | -- | -- | -- | -1,692.93 | -- | -0.5009 | 0.614 | -- | -- | -- | -255.12 | -- | -- | -- |
| ELEVAI Labs Inc | 2.45m | -5.47m | 10.46m | 18.00 | -- | 0.1166 | -- | 4.27 | -0.2924 | -0.2924 | 0.1303 | 0.1733 | 0.3826 | 0.9499 | 216.67 | 135,897.80 | -85.53 | -- | -121.34 | -- | 71.15 | -- | -223.57 | -- | 3.40 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 10.46m | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.89m | 10.66m | 7.00 | -- | 1.77 | -- | -- | -1.72 | -1.72 | 0.00 | 0.5887 | 0.00 | -- | -- | 0.00 | -114.42 | -66.55 | -138.96 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Viaderma Inc | 17.80m | 2.31m | 10.73m | 75.00 | 0.0005 | 0.00003 | 1.98 | 0.603 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.42m | 10.86m | 81.00 | -- | 0.2488 | -- | -- | -3.23 | -3.23 | 0.00 | 1.89 | 0.00 | -- | -- | 0.00 | -78.42 | -- | -91.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -1.92m | 10.93m | -- | -- | -- | -- | -- | -0.012 | -0.012 | 0.00 | -0.003 | 0.00 | -- | -- | -- | -1,256.81 | -708.50 | -- | -- | -- | -- | -- | -589.83 | -- | -- | -- | -- | -- | -- | 25.47 | -- | -- | -- |
| Conduit Pharmaceuticals Inc | 0.00 | -13.62m | 11.10m | 7.00 | -- | -- | -- | -- | -0.1708 | -0.1708 | 0.00 | -0.095 | 0.00 | -- | -- | 0.00 | -181.43 | -- | -- | -- | -- | -- | -- | -- | -- | -20.00 | -- | -- | -- | -- | 89.05 | -- | -- | -- |
| Apollomics Inc | 0.00 | -57.11m | 11.14m | 45.00 | -- | 0.5338 | -- | -- | -0.568 | -0.568 | 0.00 | 0.1892 | 0.00 | -- | -- | 0.00 | -107.81 | -- | -144.29 | -- | -- | -- | -- | -- | -- | -- | 0.185 | -- | -- | -- | 28.33 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.43m | 4.00 | -- | -- | -- | 15,238.12 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Yorkville Advisors Global LPas of 31 Dec 2023 | 966.31k | 0.56% |
